Table 5.
Univariate HR (95% CI) |
P | Multivariate HR (95% CI) |
P | |
---|---|---|---|---|
Negative Gαs | 5.832 (3.232–10.763) | <0.001* | 3.904 (1.278–5.873) | <0.001* |
Age at diagnosis | 1.098 (0.921–1.284) | 0.495 | 1.328 (0.493–4.187) | 0.276 |
Clinical stage at diagnosis | 2.287 (1.639–3.121) | <0.001* | 0.723 (0.298–1.114) | 0.294 |
Gleason score at diagnosis | 3.809 (2.778–5.132) | <0.001* | 2.153 (1.471–9.357) | 0.004* |
Preoperative PSA | 2.673 (2.007–3.297) | <0.001* | 2.158 (0.622–3.192) | 0.429 |
Angiolymphatic invasion | 1.224 (1.098–1.989) | 0.004* | 1.472 (0.897–1.677) | 0.172 |
Extraprostatic extension | 1.327 (1.211–2.019) | 0.031* | 0.819 (0.531–1.396) | 0.491 |
Positive margin | 2.127 (1.271–4.918) | 0.009* | 1.211 (0.682–2.198) | 0.514 |
Seminal vesicle invasion | 1.778 (1.281–3.711) | 0.046* | 1.397 (0.723–2.187) | 0.283 |
Positive lymph node | 1.698 (0.831–3.781) | 0.064 | 0.931 (0.871–2.011) | 0.592 |
CI: confidence interval; HR: hazard ratio; rec: recurrence.
*Significant relationships of clinical factors with overall survival.